Suppr超能文献

成人手术后预防慢性疼痛的药物治疗:更新的系统评价和荟萃分析。

Pharmacotherapy for the Prevention of Chronic Pain after Surgery in Adults: An Updated Systematic Review and Meta-analysis.

出版信息

Anesthesiology. 2021 Aug 1;135(2):304-325. doi: 10.1097/ALN.0000000000003837.

Abstract

BACKGROUND

Chronic postsurgical pain can severely impair patient health and quality of life. This systematic review update evaluated the effectiveness of systemic drugs to prevent chronic postsurgical pain.

METHODS

The authors included double-blind, placebo-controlled, randomized controlled trials including adults that evaluated perioperative systemic drugs. Studies that evaluated same drug(s) administered similarly were pooled. The primary outcome was the proportion reporting any pain at 3 or more months postsurgery.

RESULTS

The authors identified 70 new studies and 40 from 2013. Most evaluated ketamine, pregabalin, gabapentin, IV lidocaine, nonsteroidal anti-inflammatory drugs, and corticosteroids. Some meta-analyses showed statistically significant-but of unclear clinical relevance-reductions in chronic postsurgical pain prevalence after treatment with pregabalin, IV lidocaine, and nonsteroidal anti-inflammatory drugs. Meta-analyses with more than three studies and more than 500 participants showed no effect of ketamine on prevalence of any pain at 6 months when administered for 24 h or less (risk ratio, 0.62 [95% CI, 0.36 to 1.07]; prevalence, 0 to 88% ketamine; 0 to 94% placebo) or more than 24 h (risk ratio, 0.91 [95% CI, 0.74 to 1.12]; 6 to 71% ketamine; 5 to 78% placebo), no effect of pregabalin on prevalence of any pain at 3 months (risk ratio, 0.88 [95% CI, 0.70 to 1.10]; 4 to 88% pregabalin; 3 to 80% placebo) or 6 months (risk ratio, 0.78 [95% CI, 0.47 to 1.28]; 6 to 68% pregabalin; 4 to 69% placebo) when administered more than 24 h, and an effect of pregabalin on prevalence of moderate/severe pain at 3 months when administered more than 24 h (risk ratio, 0.47 [95% CI, 0.33 to 0.68]; 0 to 20% pregabalin; 4 to 34% placebo). However, the results should be interpreted with caution given small study sizes, variable surgical types, dosages, timing and method of outcome measurements in relation to the acute pain trajectory in question, and preoperative pain status.

CONCLUSIONS

Despite agreement that chronic postsurgical pain is an important topic, extremely little progress has been made since 2013, likely due to study designs being insufficient to address the complexities of this multifactorial problem.

摘要

背景

慢性术后疼痛可严重损害患者的健康和生活质量。本系统评价更新评估了预防慢性术后疼痛的全身药物的有效性。

方法

作者纳入了包括评估围手术期全身药物的成年人的双盲、安慰剂对照、随机对照试验。评估相同药物(以相似方式给予)的研究被汇总在一起。主要结局是报告术后 3 个月或以上任何疼痛的比例。

结果

作者确定了 70 项新研究和 2013 年的 40 项研究。大多数研究评估了氯胺酮、普瑞巴林、加巴喷丁、静脉利多卡因、非甾体抗炎药和皮质类固醇。一些荟萃分析显示,普瑞巴林、静脉利多卡因和非甾体抗炎药治疗后,慢性术后疼痛的患病率有统计学意义,但临床相关性不明确。荟萃分析显示,在 6 个月时,给予氯胺酮治疗 24 小时或更短时间(风险比,0.62 [95%置信区间,0.36 至 1.07];普瑞巴林组患病率为 0 至 88%,安慰剂组为 0 至 94%)或超过 24 小时(风险比,0.91 [95%置信区间,0.74 至 1.12];普瑞巴林组患病率为 6 至 71%,安慰剂组为 5 至 78%)时,氯胺酮对任何疼痛的发生率无影响;普瑞巴林组在 3 个月时(风险比,0.88 [95%置信区间,0.70 至 1.10];普瑞巴林组 4 至 88%,安慰剂组 3 至 80%)或 6 个月时(风险比,0.78 [95%置信区间,0.47 至 1.28];普瑞巴林组 6 至 68%,安慰剂组 4 至 69%),当给予超过 24 小时时,普瑞巴林对任何疼痛的发生率无影响;普瑞巴林对 3 个月时中度/重度疼痛的发生率有影响,当给予超过 24 小时时(风险比,0.47 [95%置信区间,0.33 至 0.68];普瑞巴林组 0 至 20%,安慰剂组 4 至 34%)。然而,鉴于研究规模较小、手术类型、剂量、与急性疼痛轨迹相关的时间和结局测量方法以及术前疼痛状况的差异,结果应谨慎解释。

结论

尽管人们一致认为慢性术后疼痛是一个重要的话题,但自 2013 年以来几乎没有取得进展,这可能是由于研究设计不足以解决这个多因素问题的复杂性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验